Cidara TherapeuticsCDTX
13F holders, Q1 2025 (March 31)At the end of Q1 2025, 46 institutions reported holding Cidara Therapeutics Inc. (CDTX) in their 13F filings, up 6 from Q4 2024. 8 opened new positions and 2 sold out. The largest holders were Ra Capital Management, L.P. ($23.5M), Venrock Adviser, LLC ($22.6M) and TCG Crossover Management, LLC ($21.7M). 4 famous investors held it, including Steve Cohen (0.0% of Point72 Asset Management's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Cidara Therapeutics Inc.
- CUSIP
- 171757206
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $20.6M |
| Exits | 2 | $1.3M |
All 13F filers, Q4 2024 → Q1 2025: 3,040,652 shares bought and 354,934 shares sold, net +2,685,718 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 46 holders
| Ra Capital Management, L.P. | 0.39% | No change | 1,092,796 | $23.5M |
| Venrock Adviser, LLC | 1.93% | Add +37.3% | 1,051,518 | $22.6M |
| TCG Crossover Management, LLC | 2.96% | No change | 1,005,901 | $21.7M |
| Adage Capital Partners Gp, L.L.C. | 0.04% | Add +167.6% | 990,000 | $21.3M |
| BVF Inc. | 0.81% | Reduce -15.4% | 924,642 | $19.9M |
| Bain Capital Life Sciences Investors, LLC | 2.24% | No change | 703,080 | $15.1M |
| Vivo Capital, LLC | 1.95% | Add +2.0% | 684,276 | $14.7M |
| Vanguard Group Inc. | 0.00% | Add +134.3% | 509,576 | $11.0M |
| Vestal Point Capital, LP | 0.78% | New | 504,542 | $10.9M |
| Susquehanna International Group, LLP | 0.01% | Add +703.5% | 342,476 | $7.4M |
| Citadel Advisors | 0.01% | New | 287,775 | $6.2M |
| Ikarian Capital, LLC | 1.75% | Add +361.5% | 248,940 | $5.4M |
| Acuta Capital Partners, LLC | 3.14% | Add +130.8% | 125,708 | $2.7M |
| Aberdeen Group plc | 0.01% | New | 120,879 | $2.6M |
| Point72 Asset Management | 0.01% | Add +1751.9% | 113,855 | $2.5M |
| Checkpoint Capital L.P. | 1.23% | Reduce -47.0% | 104,380 | $2.2M |
| Renaissance Technologies | 0.00% | Reduce -3.2% | 92,517 | $2.0M |
| Boothbay Fund Management, LLC | 0.06% | Add +406.9% | 79,081 | $1.7M |
| UBS Group AG | 0.00% | Add +42.5% | 66,813 | $1.4M |
| Millennium Management | 0.00% | Add +76.8% | 63,580 | $1.4M |
| 5AM Venture Management, LLC | 0.46% | No change | 56,725 | $1.2M |
| Geode Capital Management, LLC | 0.00% | Add +3.6% | 54,983 | $1.2M |
| BlackRock, Inc. | 0.00% | Reduce -4.7% | 52,896 | $1.1M |
| Goldman Sachs Group Inc. | 0.00% | Add +203.8% | 42,143 | $908K |
| Northern Trust Corp. | 0.00% | Reduce -1.2% | 33,560 | $723K |
| Jane Street Group, LLC | 0.00% | Add +119.0% | 27,849 | $600K |
| Bank of America Corp. | 0.00% | Add +54902.0% | 27,501 | $592K |
| State Street Corp. | 0.00% | Add +18.4% | 22,576 | $486K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -57.4% | 21,124 | $455K |
| ADAR1 Capital Management, LLC | 0.09% | Reduce -16.0% | 20,938 | $451K |
| OMERS ADMINISTRATION Corp | 0.00% | Add +53.2% | 19,300 | $416K |
| Sphera Funds Management LTD. | 0.09% | New | 17,128 | $369K |
| Alethea Capital Management, LLC | 0.23% | No change | 14,311 | $308K |
| West Michigan Advisors, LLC | 0.10% | New | 13,500 | $291K |
| American Century Companies Inc. | 0.00% | New | 10,409 | $224K |
| Morgan Stanley | 0.00% | Add +238.2% | 8,217 | $177K |
| Point72 Asia (Singapore) Pte. Ltd. | 0.01% | Reduce -25.6% | 1,552 | $33K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 933 | $20K |
| Citigroup Inc. | 0.00% | Reduce -92.4% | 577 | $12K |
| Point72 (DIFC) Ltd | 0.00% | Add +136.9% | 469 | $10K |
| Avion Wealth | 0.00% | No change | 250 | $6K |
| Allworth Financial LP | 0.00% | No change | 40 | $860 |
| Barclays PLC | 0.00% | New | 28 | $603 |
| SBI Securities Co., Ltd. | 0.00% | No change | 20 | $431 |
| BNP Paribas Financial Markets | 0.00% | No change | 17 | $366 |
| JPMorgan Chase & Co. | 0.00% | No change | 6 | $129 |
"% of holder's portfolio" is CDTX's weight in each manager's 13F, not the share of Cidara Therapeutics Inc. the manager owns.